• 100units/ml suspension for injection 10ml vial

• Approved Humulin® I formulations include:
  
  • 5x3ml cartridges;
  • 5x3ml pens. 

• 100 units/mL cartridges
• Approved for use in patients with Type 1 diabetes with
  
  • Nocturnal/Severe Hypogycaemia (with or without hypoglycaemic unawareness) in patients who would otherwsie progress to insuling pump treatment as per NICE TA151); or
  • Recurrent DKA episodes despite good compliance and who would otherwise progress to insulin pump therapy
  • Paediatric patients who cannot tolerate glargine sting
  • Paediatric patients with poor control on the high HbA1c pathway
  • Patients or Parents/Carers with unpredictable lifestyles such as students or shift workers.

“**Note that there are two strengths of Tresiba® (insulin degludec). Caution should be exercised when prescribing and dispensing**

• 200 units/mL
• Pre-filled pen
• Approved for use in patients with Type 1 diabetes with
  
  • Nocturnal/Severe Hypogycaemia (with or without hypoglycaemic unawareness) in patients who would otherwise progress to insulin pump treatment as per NICE TA151; or
  • Recurrent DKA episodes despite good compliance and who would otherwise progress to insulin pump therapy
  • Paediatric patients who cannot tolerate glargine sting
  • Paediatric patients with poor control on the high HbA1c pathway
  • Patients or Parents/Carers with unpredictable lifestyles such as students or shift workers.

**Note that there are two strengths of Tresiba^® (insulin degludec). Caution should be exercised when prescribing and dispensing**

• Alternative choice long acting basal insulin.
• Approved Levemir® formualtions include:
  
  • 5x3ml cartridges;
  • 5x3ml pens. 

NB: This product is being discontinued (stock expected to be exhausted by December 2026). No new patients should be initiated on this product

Guidance on managing the discontinuation is available from the Association of British Diabetologists and Primary Care Diabetes and Obesity Society. 

• Alternative choice long acting basal insulin. 
• Approved Lantus® formulations include:
  
  • 10ml vials;
  • 5x3ml cartridges;
  • 5x3ml pens (Solostar® - in line with NICE). 

• Alternative choice long acting basal insulin.
• Approved Toujeo® formulations include:
  • 1.5mL pre-filled pen (Solostar): Dose range 1-80 units in 1 unit increments. 450 units in a pen
  • 3mL pre-filled pen (DoubleStar): Dose range 2-160 units in 2 unit increments. 900 units in a pen.

**CARE: HIGH STRENGTH INSULIN**

Approved for use in patients on insulin glargine who require:

• High dose (60+ units per dose for Toujeo SoloStar and 80+ units per dose for DoubleStar
• Large volume of insulin and local site reactions
• Twice daily insulin

NOTE: Toujeo 300 units/ml is not bioequivalent to insulin glargine 100 units/ml and is not directly interchangeable

• Alternative choice long acting basal insulin. 
• Approved formulations include:
  • 5x3ml cartridge
  • 5x3ml Kwikpen®.

• Alternative choice long acting basal insulin. 
• Approved formulations include:
  • 5x3ml pre-filled pen